CALIWAY BIOPHARMACEUTICALS Business Summary

Caliway Biopharmaceuticals Ltd (6919.TW) is a clinical-stage biotechnology firm specializing in the discovery and development of small-molecule therapeutics for aesthetic medicine and chronic inflammatory diseases. The company’s primary business model centers on advancing its proprietary R&D pipeline toward global licensing agreements and commercial partnerships, while currently generating ancillary revenue through the distribution of health food products in Taiwan and China. Its core business segments are divided into medical aesthetics, targeting non-surgical fat reduction and cellulite, and therapeutic medicine, focusing on conditions like Dercum’s disease and osteoarthritis. Caliway’s lead candidate, CBL-514, is a first-in-class injectable lipolysis drug currently in pivotal Phase 3 global trials (SUPREME-01 and SUPREME-02), positioning the firm as a disruptive innovator against established industry giants such as AbbVie (Allergan), Galderma, and Merz Aesthetics. Unlike competitors’ cryolipolysis devices (CoolSculpting) or necrosis-inducing injectables (Kybella), Caliway’s platform focuses on inducing targeted adipocyte apoptosis, offering a safer and more precise alternative for large-area localized fat reduction. Founded in 2012, the company is led by a management team with extensive pedigree in pharmaceutical commercialization and regulatory affairs. Vivian Ling serves as the Chief Executive Officer and Chief R&D Officer, overseeing the technical development of the company’s nanoparticle and lead-compound screening platforms. She is supported by President Antony Hsu, who directs business development, fundraising, and global launch planning, and Vice President Laura Chung, who brings over 22 years of experience in multinational licensing and regional market expansion. The scientific direction is further bolstered by Dr. Kao-Jung Chang, who leads clinical application strategies. Caliway is a publicly traded entity on the Taiwan Stock Exchange, with a shareholder base that includes institutional investors such as State Street Global Advisors and Sumiseki Holdings, reflecting strong market confidence in its multi-indication strategy and first-in-class drug candidates.